VISYNC
LIVE

Serial Number

79423184

Owner

VISYNC TECHNOLOGIES, S.A.

Attorney

R. Peter Spies

Filing Date

Dec 12, 2024

Add to watchlist:

No watchlists yet
View on USPTO

VISYNC Trademark

Serial Number: 79423184

VISYNC is a trademark filed by VISYNC TECHNOLOGIES, S.A. on December 12, 2024. The trademark is classified under Class 5 (Pharmaceuticals), Class 10 (Medical Apparatus), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently pending registration.

Owner Contact Info

VISYNC TECHNOLOGIES, S.A.

Av. República, Quinta do Marquês Edifício

Entity Type: 98

Trademark Details

Filing Date

December 12, 2024

Registration Date

Not Registered

Goods & Services

Surgical, medical and veterinary apparatus and instruments for medical, dental or veterinary use; medical apparatus and instruments, namely, drug delivery devices, sold empty, in the nature of syringes, infusion sets, inhalers and diagnostic apparatus for medical purposes used in medical laboratories for testing blood sugar levels, cancer cells, DNA; diagnostic, examination and monitoring equipment in the nature of imaging equipment, microscopes, blood analysers (haematology analysers), biochemistry analysers, immunoassay analysers, microbiology incubators, centrifuges.

Pharmaceuticals, medical and veterinary preparations all of the foregoing for the prevention, diagnosis, treatment of or improvement of conditions and disorders, namely, inflammatory, allergical, oncological, degenerative, genetic, traumatic, tumoural, pressure, poisoning, mutation, sepsis, psychiatric, obese, eating, addictive, sexual, sleep, and infectious conditions and disorders, namely, bacterial, viral, fungal or parasitic conditions and disorders; all of the above related to skin, musculo-skeletal, cardiac, neurological, cellular, vascular, hematological, respiratory, digestive, genital, urinary, reproductive, sensorial, metabolic, endocrine, lymphatic, immune or nervous systems, as well as pain management, for use by humans or animals; biopharmaceutical preparations for the treatment of inflammatory, allergical, oncological, degenerative, genetic, traumatic, tumoural, pressure, poisoning, mutation, sepsis, psychiatric, obese, eating, addictive, sexual, sleep, and infectious conditions and disorders, namely, bacterial, viral, fungal or parasitic conditions and disorders and advanced therapy medicinal products (atmps), namely, Gene Therapy Medicinal Products (GTMPs), Somatic Cell Therapy Medicinal Products (sCTMPs), Tissue Engineered Products (TEPs), and Combined ATMPs; medicines for human use that are based on genes, tissues or cells for the prevention, diagnosis, treatment of or improvement of conditions and disorders, namely, inflammatory, allergical, oncological, degenerative, genetic, traumatic, tumoural, pressure, poisoning, mutation, sepsis, psychiatric, obese, eating, addictive, sexual, sleep, and infectious conditions and disorders, namely, bacterial, viral, fungal or parasitic conditions and disorders; all of the above related to skin, musculo-skeletal, cardiac, neurological, cellular, vascular, hematological, respiratory, digestive, genital, urinary, reproductive, sensorial, metabolic, endocrine, lymphatic, immune or nervous systems, as well as pain management; drugs for medical purposes, namely, pharmaceutical preparations for the prevention, diagnosis, treatment of or improvement of conditions and disorders, namely, inflammatory, allergical, oncological, degenerative, genetic, traumatic, tumoural, pressure, poisoning, mutation, sepsis, psychiatric, obese, eating, addictive, sexual, sleep, and infectious conditions and disorders, namely, bacterial, viral, fungal or parasitic conditions and disorders; all of the above related to skin, musculo-skeletal, cardiac, neurological, cellular, vascular, hematological, respiratory, digestive, genital, urinary, reproductive, sensorial, metabolic, endocrine, lymphatic, immune or nervous systems, as well as pain management; pharmaceutical preparations for the prevention, diagnosis, treatment of or improvement of conditions and disorders, namely, inflammatory, allergical, oncological, degenerative, genetic, traumatic, tumoural, pressure, poisoning, mutation, sepsis, psychiatric, obese, eating, addictive, sexual, sleep, and infectious conditions and disorders, namely, bacterial, viral, fungal or parasitic conditions and disorders; all of the above related to skin, musculo-skeletal, cardiac, neurological, cellular, vascular, hematological, respiratory, digestive, genital, urinary, reproductive, sensorial, metabolic, endocrine, lymphatic, immune or nervous systems, as well as pain management; biopharmaceutical preparations for the prevention, diagnosis, treatment of or improvement of conditions and disorders, namely, inflammatory, allergical, oncological, degenerative, genetic, traumatic, tumoural, pressure, poisoning, mutation, sepsis, psychiatric, obese, eating, addictive, sexual, sleep, and infectious conditions and disorders, namely, bacterial, viral, fungal or parasitic conditions and disorders; all of the above related to skin, musculo-skeletal, cardiac, neurological, cellular, vascular, hematological, respiratory, digestive, genital, urinary, reproductive, sensorial, metabolic, endocrine, lymphatic, immune or nervous systems, as well as pain management and advanced therapy medicinal products (atmps) for systemic or targeted delivery, namely, nasal spray preparations suitable for nasal delivery, nose-to-brain delivery for medical purposes; advanced therapy medicinal products (atmps), namely, Gene Therapy Medicinal Products (GTMPs), Somatic Cell Therapy Medicinal Products (sCTMPs), Tissue Engineered Products (TEPs), and Combined ATMPs, medical and veterinary preparations, namely, medical and veterinary preparations comprising biomolecules, cells, viruses, virus-like particles, exosomes, nanoparticles or liposomes for the prevention, diagnosis, treatment of or improvement of conditions and disorders, namely, inflammatory, allergical, oncological, degenerative, genetic, traumatic, tumoural, pressure, poisoning, mutation, sepsis, psychiatric, obese, eating, addictive, sexual, sleep, and infectious conditions and disorders, namely, bacterial, viral, fungal or parasitic conditions and disorders; all of the above related to skin, musculo-skeletal, cardiac, neurological, cellular, vascular, hematological, respiratory, digestive, genital, urinary, reproductive, sensorial, metabolic, endocrine, lymphatic, immune or nervous systems, as well as pain management; vaccines; diagnostic preparations for medical purposes; diagnostic preparations for veterinary purposes; diagnostic reagents and kits consisting primarily of probes, buffers and reagents for use in microbial testing.

Medical diagnostic services; handling of blood samples in the nature of blood testing being medical analysis services for diagnostic and treatment purposes provided by medical laboratories; performing diagnosis of diseases

Scientific and technological consulting services in the pharmaceutical industry and research and design relating thereto; industrial analysis in the nature of product testing, industrial research and industrial design services in the field of pharmaceutical, veterinary and medical goods; quality control of services for others and providing user authentication services using single sign-on technology for online software applications; pharmaceutical and biological analysis and research services; medical research relating to the research, development and manufacturing activities in the field of medicines, namely biomolecules, cells, viruses, virus-like particles, exosomes, nanoparticles, liposomes and vaccines; medical research relating to the research, development and manufacturing activities in the field of delivery of medicines namely, nasal spray preparations suitable for nasal delivery, nose-to-brain delivery; technological research being research and development of manufacturing processes for the pharmaceutical industry; optimization of processes in the nature of technological consultancy services for search engine optimization for the pharmaceutical industry; design and development of medical diagnostic apparatus for detecting inflammatory, allergical, oncological, degenerative, genetic, traumatic, tumoural, pressure, poisoning, mutation, sepsis, psychiatric, obese, eating, addictive, sexual, sleep, and infectious conditions and disorders, namely, bacterial, viral, fungal or parasitic conditions and disorders; scientific research for medical purposes in the area of inflammatory, allergical, oncological, degenerative, genetic, traumatic, tumoural, pressure, poisoning, mutation, sepsis, psychiatric, obese, eating, addictive, sexual, sleep, and infectious conditions and disorders, namely, bacterial, viral, fungal or parasitic conditions and disorders.

Filing History

NOTIFICATION OF FINAL REFUSAL EMAILED
Feb 21, 2026 GNFN
FINAL REFUSAL E-MAILED
Feb 21, 2026 GNFR
FINAL REFUSAL WRITTEN
Feb 21, 2026 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Jan 28, 2026 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jan 28, 2026 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jan 28, 2026 TROA
REFUSAL PROCESSED BY IB
Aug 16, 2025 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Jul 28, 2025 RFCS
REFUSAL PROCESSED BY MPU
Jul 28, 2025 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Jun 5, 2025 RFCR
NON-FINAL ACTION WRITTEN
Jun 4, 2025 CNRT
ASSIGNED TO EXAMINER
May 30, 2025 DOCK
APPLICATION FILING RECEIPT MAILED
May 9, 2025 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
May 9, 2025 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
May 8, 2025 REPR